TFPI Protein, Human, Recombinant (His & Avi)

Oestrogens influence the pathophysiology and development of hormone-sensitive cancers, such as breast cancer. Tissue factor pathway inhibitor (TFPI) is a serine protease inhibitor of the extrinsic coagulation pathway and has recently been associated with breast cancer cell development.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 442.00
500 μg	5 days	$ 1,760.00
1 mg	5 days	$ 2,950.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 442.00

500 μg

5 days

$ 1,760.00

1 mg

5 days

$ 2,950.00

Description

Species	Human
Expression System	HEK293
Tag	C-His-Avi
Accession Number	P10646-1
Synonyms	LACI, EPI, TFPI, convertin, TFI, TFPI1
Construction	Recombinant Human TFPI Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Asp29-Lys282.[Accession \|P10646-1]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 32.1 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Stability & Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	Oestrogens influence the pathophysiology and development of hormone-sensitive cancers, such as breast cancer. Tissue factor pathway inhibitor (TFPI) is a serine protease inhibitor of the extrinsic coagulation pathway and has recently been associated with breast cancer cell development.